NewAmsterdam Pharma Company N.V.
NAMS
$35.26
-$0.59-1.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -314.68% | 56.07% | 57.12% | -453.72% | 57.32% |
| Total Depreciation and Amortization | 42.22% | -13.46% | 1.96% | 82.14% | 47.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 993.93% | 147.54% | -111.73% | 1,431.55% | 1,107.14% |
| Change in Net Operating Assets | 104.12% | -330.34% | 229.71% | -28,600.00% | 100.19% |
| Cash from Operations | 13.01% | -3.30% | 2.70% | -199.80% | 76.84% |
| Capital Expenditure | 52.27% | -450.00% | -433.33% | 96.00% | 64.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.60% | -5,639.81% | 104.62% | -- | -- |
| Cash from Investing | 101.57% | -5,673.94% | 104.59% | -82,805.33% | 64.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 72.03% | -57.74% | -98.23% | 787,203.45% | -98.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -6,244.00% | -- | -- |
| Cash from Financing | 72.03% | -47.46% | -98.57% | 787,160.34% | -98.75% |
| Foreign Exchange rate Adjustments | -97.48% | 134.05% | 147.51% | -274.82% | 599.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.92% | -691.30% | -106.68% | 4,474.16% | 84.18% |